A rare case of MYH9 disorders presenting with macrothrombocytopenia and deafness caused by MYH9-R702C mutation.

[1]  C. Fiore,et al.  Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome). , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  P. Noris,et al.  Position of nonmuscle myosin heavy chain IIA (NMMHC‐IIA) mutations predicts the natural history of MYH9‐related disease , 2008, Human mutation.

[3]  M. Poon.  The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders. , 2007, Transfusion medicine reviews.

[4]  H. Saito,et al.  Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations , 2007, European journal of haematology.

[5]  M. Kelley,et al.  Genotype–phenotype correlation in MYH9‐related thrombocytopenia , 2005, British journal of haematology.

[6]  P. D. de Groot,et al.  Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count , 2005, Journal of thrombosis and haemostasis : JTH.

[7]  R. Ravazzolo,et al.  MYH9-Related Disease: May-Hegglin Anomaly, Sebastian Syndrome, Fechtner Syndrome, and Epstein Syndrome Are not Distinct Entities but Represent a Variable Expression of a Single Illness , 2003, Medicine.

[8]  H. Saito,et al.  Immunofluorescence Analysis of Neutrophil Nonmuscle Myosin Heavy Chain-A in MYH9 Disorders: Association of Subcellular Localization with MYH9 Mutations , 2003, Laboratory Investigation.

[9]  H. Saito,et al.  Identification of six novel MYH9 mutations and genotype-phenotype relationships in autosomal dominant macrothrombocytopenia with leukocyte inclusions , 2001, Journal of Human Genetics.

[10]  J. White,et al.  Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. , 2001, American journal of human genetics.

[11]  Toshihiro Tanaka,et al.  Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome). , 2001, Blood.

[12]  U Magrini,et al.  Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. , 2000, Nature genetics.

[13]  T. Ortel,et al.  Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly , 2000, Nature Genetics.

[14]  C. Epstein,et al.  Hereditary macrothrombocytopathia, nephritis and deafness. , 1972, The American journal of medicine.